Aldeyra Therapeutics, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Aldeyra Therapeutics, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Cash Cushion Ratio: Cash, after subtracting all debt, is 1.4 times its market value (net cash). Higher than 92% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Data incomplete
Self-Funding Ratio
—Data incomplete
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
0/3 · 2/3Sales grew in 0 of the last 3 years; profit grew in 2 of 3.
Less steady than 70% of Healthcare companies in United States.
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
-2.2×Operating cash was negative last year, while some debt falls due within a year.
Higher than 63% of Healthcare companies in United States.
Cash Cushion Ratio
1.4× cashCash, after subtracting all debt, is 1.4 times its market value (net cash).
Higher than 92% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (11)
Aldeyra Therapeutics, Inc. made a loss over the last year. Aldeyra Therapeutics, Inc. owes $0.20 for every $1 it owns. Aldeyra Therapeutics, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossAldeyra Therapeutics, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
1.03The share price is 1.03 times Aldeyra Therapeutics, Inc.'s book value per share, lower than 78% of Healthcare companies in United States.
Market cap
$39 MThe total market value of all of Aldeyra Therapeutics, Inc.'s shares at today's price (share price × number of shares), smaller than 76% of Healthcare companies in United States. PosiCap size class: Micro Cap.
Net worth (book value)
$38 MWhat Aldeyra Therapeutics, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$0.63Net worth divided by the number of shares. The share price of $0.65 is 1.0 times this, which is the P/B above.
Return on equity (ROE)
-49.5%Aldeyra Therapeutics, Inc. lost 49.5% of its shareholders' money over the last year, lower than 51% of Healthcare companies in United States.
Owes vs Owns
0.20×Aldeyra Therapeutics, Inc. owes $0.20 for every $1 it owns (low), lower than 72% of Healthcare companies in United States.
Dividend yield
NoneAldeyra Therapeutics, Inc. does not currently pay a dividend.
Profit growth
LossAldeyra Therapeutics, Inc. made a loss in each of the last two years.
Interest cover
Not coveredAldeyra Therapeutics, Inc.'s operating profit did not cover its interest costs in the year to Dec 2025.
Cash vs debt
Net cashAldeyra Therapeutics, Inc. held $55 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Aldeyra Therapeutics, Inc.: $39 M ÷ $38 M (30 Jun 2026) = 1.0.
What is Aldeyra Therapeutics, Inc.'s return on equity?
Aldeyra Therapeutics, Inc. lost 49.5% of its shareholders' money over the last year, lower than 51% of Healthcare companies in United States.
How much does Aldeyra Therapeutics, Inc. owe compared with what it owns?
Aldeyra Therapeutics, Inc. owes $0.20 for every $1 it owns (low), lower than 72% of Healthcare companies in United States.
Does Aldeyra Therapeutics, Inc. pay a dividend?
No. Aldeyra Therapeutics, Inc. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.